Home › NDC Lookup › Ingredients › Econazole Nitrate › 73352-0100-70
Econazole Nitrate 10 mg/g Aerosol, Foam — NDC 73352-0100-70 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 73352-0100-70: Econazole Nitrate 10 mg/g Aerosol, Foam

by Trifluent Pharma, LLC · 1 CANISTER in 1 CARTON / 70 g in 1 CANISTER

This is a package of Econazole Nitrate 10 mg/g Aerosol, Foam from Trifluent Pharma, LLC, first listed with the FDA Sep 2025 and currently FDA-listed. It is this product's only package size.

🏷️ FDA NDC (as labeled) 73352-100-70 billing pads the product segment with a zero
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 73352-100-70 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
73352 labeler · 100 product · 70 package
Package marketed since
Sep 13, 2025
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC)
0373352100705
Medicaid fills, this package
234 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 73352-100-70
Product NDC 73352-100
11-digit billing NDC 73352010070
NCPDP billing unit GM — per gram (weight)
RxCUI 1442585
UNII H438WYN10E
UPC 0373352100705
Application # NDA205175
SPL Set ID 3eb40c94-f369-ce4b-e063-6294a90abed4
Established class (EPC) Azole Antifungal
Chemical class Azoles
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2025-09-13
Route TOPICAL
Dosage form AEROSOL, FOAM
Substance ECONAZOLE NITRATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90154035103910
GCN Seq No 071812
GCN 35806
HICL code 016904
Ingredient (HICL) Econazole Nitrate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 84:04.08.08
AHFS class Azoles (Skin And Mucous Membrane)
FDB label name ECONAZOLE NITRATE 1% FOAM
FDB brand name Econazole Nitrate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 071812
  • GCN: 35806
  • GPI-14 (Medi-Span): 90154035103910
  • HICL (First Databank): 016904
  • AHFS class code: 84:04.08.08
  • RxCUI (RxNorm): 1442585
Why two NDCs? The FDA registers this code as 73352-100-70 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 73352-0100-70. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Azole Antifungal class.

Pharmacologic class Azole Antifungal
Drug family (ATC) Imidazole and triazole derivatives, Imidazole derivatives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ECONAZOLE NITRATE 1% FOAM Ingredient Econazole Nitrate
📖 What it is MedlinePlus · NLM

Econazole is used to treat skin infections such as athlete's foot, jock itch, and ringworm. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats fungal skin infections. The foam is for athlete's foot between the toes in people 12 and older. The cream is used for athlete's foot, ringworm of the groin and body, tine...
  • The cream goes on once a day for most tinea infections and twice a day for skin yeast infections. The foam is used once daily for athlete's foot. Follow your prescriber's direction...
  • Keep going even if you feel better early. The cream is typically used for two weeks for yeast infections, groin and body ringworm, and one month for athlete's foot. This lowers the...
  • Side effects are uncommon. In foam trials, skin reactions where it was applied happened in less than 1% of people, about the same as the foam without medicine.
📖 Read our full Econazole Topical guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $23.72 $1,660.39 / 70 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
73352-0100-70 You're viewing this Main listing 1 CANISTER in 1 CARTON / 70 g in 1 CANISTER 2025-09-13 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Econazole Nitrate 10 mg/gthis 73352-0100-70 Trifluent 1 canister — — FDA listed —
Ecoza 10 mg/g 81811-0100-70 Resilia 1 canister — — FDA listed —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2013
First FDA approval
Oct 2013
📍
2026
Currently FDA-listed
13 years listed
🛡️
2031
Latest patent/protection listed
not a guaranteed launch date
🔒No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.

🛡️ Latest patent/protection date listed: FDA patent/protection data lists protections through Aug 2031. This may affect when a full generic version becomes widely available, but it is not a guaranteed launch date.
📅 FDA approved Oct 24, 2013 RLD RS ⏳ ~4.7 yr to latest listed protection

Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.

Patents & exclusivity — FDA Orange Book
US 10071054 — drug product
2013 2015 2017 2019 2021 2023 2025 2027 2029 2031
Today
LOE
Substance patent Formulation patent Method-of-use patent Exclusivity Pediatric +6mo
🏛️FDA exclusivity
FDA-granted marketing protection. It’s separate from patents and may be shorter than patent protection.
🧪Product / substance patents
Patents covering the active ingredient, product, formulation, or related drug features.
🎯Method-of-use patents
Patents covering specific approved uses. These can sometimes be carved out with a “skinny label,” but not always.
🛈 What do these terms mean?
Patent
Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
Substance patent
Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
Formulation (product) patent
Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
Method-of-use patent
A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
Skinny label
A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
Exclusivity
FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
Paragraph IV
A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
RLD / RS
Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
TE / AB rating
FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
LOE (loss of exclusivity)
The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.

Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.

Listed patents (1)
PatentTypeUse codeExpires
US 10071054 ↗ Drug product — Aug 8, 2031
Common questions
Is there a generic version of ECONAZOLE NITRATE 1% FOAM?
No FDA-approved generic equivalent is currently listed in the FDA Orange Book for ECONAZOLE NITRATE 1% FOAM. Based on the patents and exclusivity currently listed, the Orange Book estimate is that full-label generic entry may be delayed until Aug 2031 — an estimate, not a guaranteed launch date.
The FDA approved a generic — why can’t I get it at my pharmacy yet?
FDA approval and pharmacy availability are two different things. The FDA can approve a generic years before it actually reaches pharmacies, because the brand company may still hold patents or have a settlement that delays the launch. A manufacturer also has to choose to make and sell it, and have supply ready. So a drug can be “FDA-approved generic exists” and still be brand-only at the counter today.
Why do different websites show different generic release dates?
Generic availability is not based on one single date. Some sources use the first exclusivity expiration, some use the last product patent, and others use the latest method-of-use patent. Patent challenges, settlements, licenses, and label carve-outs can also change the real-world launch date. This page shows the underlying Orange Book dates so you can see why estimates may differ.
What does “FDA listed” mean?
It means the product appears in the FDA’s official NDC directory. That’s a good sign a product exists and is intended for the U.S. market, but on its own it does not confirm a pharmacy can fill it today. Where we have recent retail pricing data (NADAC) for a product, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Orange Book for a patent or exclusivity on the brand product. It can affect when a full generic version becomes widely available — but it is not a guaranteed generic launch date. Generics sometimes arrive earlier (through a settlement or patent challenge) or later (a manufacturer still has to make and sell one).
What does “current Orange Book estimate” mean?
It means we are using the latest patent and exclusivity dates currently listed in the FDA Orange Book. It is not a guaranteed launch date.
Can a generic come out before the last patent expires?
Sometimes. A generic company may challenge a patent, settle with the brand manufacturer, receive a license, or obtain approval with a narrower label that avoids a patented use. In other cases, the last listed protection may delay full-label generic competition.
Can a generic come out after the listed dates?
Yes. Even after patents or exclusivity expire, a generic still needs FDA approval and a manufacturer must choose to market it. Supply, litigation, business decisions, or regulatory issues can delay actual availability.
What is the difference between patents and exclusivity?
Patents are legal protections usually issued by the U.S. Patent and Trademark Office. FDA exclusivity is marketing protection granted by the FDA. They are separate, and either one can affect generic timing.
Why are there multiple patent dates?
One drug can have several patents covering different things: the active ingredient, a formulation, a manufacturing process, or a specific approved use. That is why a page may show several expiration dates instead of one simple generic date.
Built from FDA Orange Book patent and exclusivity data. Dates are refreshed from public FDA data when available; the marker is max(latest patent expiry, latest exclusivity expiry). Paragraph-IV settlements and first-filer 180-day exclusivity can shift the real date; a method-of-use patent may allow an earlier skinny-label generic for non-protected indications. Generic launch timing is an estimate, not a guarantee.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Econazole Topical inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 6LV4FOR43R
    Butane is a colorless gas derived from petroleum. In medicines, it serves as a propellant in inhalers and aerosol sprays, helping deliver the active drug to the lungs or skin.
  • UNII 92RU3N3Y1O
    Dimethicone is a silicone-based oil that acts as an anti-foaming agent and lubricant in medicines. It reduces gas bubbles in liquid formulations and helps coat and protect the stomach lining when ingested.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 7T1F30V5YH
    A synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together and keeps them from separating in liquid formulations.
  • UNII U725QWY32X
    Povidone K30 is a synthetic polymer made from petroleum. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the stomach so the medicine can be absorbed.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
  • UNII 9O3K93S3TK
    Trolamine is an alkaline compound used as a pH buffer and emulsifier in medicines. It helps neutralize acids, stabilize formulations, and enable mixing of oil and water-based ingredients.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

9 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTrifluent Pharma, LLC
Application holderRESILIA PHARMACEUTICALS INC
FDA applicationNDA205175 (NDA AUTHORIZED GENERIC)
Labeler code73352
First marketedSep 2025
Product typeHuman Prescription Drug
Portfolio18 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 70 words ▾

1 INDICATIONS AND USAGE Econazole nitrate topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. Econazole nitrate is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes , and Epidermophyton floccosum in patients 12 years of age and older. ( 1 )

⏱️ Dosage and Administration 67 words ▾

2 DOSAGE AND ADMINISTRATION Econazole nitrate topical foam, 1% is for topical use only. Econazole nitrate topical foam, 1% is not for oral, ophthalmic, or intravaginal use. Econazole nitrate topical foam, 1% should be applied to cover affected areas once daily for 4 weeks. For topical use only; not for oral, ophthalmic, or intravaginal use. ( 2 ) Apply once daily for 4 weeks. ( 2 )

💊 Dosage Forms and Strengths 32 words ▾

3 DOSAGE FORMS AND STRENGTHS Foam, 1%. Each gram of econazole nitrate topical foam, 1%, contains 10 mg of econazole nitrate in a white to off-white foam. Foam, 1%. ( 3 )

⛔ Contraindications 7 words ▾

4 CONTRAINDICATIONS None. None. ( 4 )

⚠️ Warnings and Cautions 75 words ▾

5 WARNINGS AND PRECAUTIONS - Contents are flammable. Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application. ( 5.1 )

5.1Flammability Econazole nitrate topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.

🤒 Adverse Reactions 195 words ▾

6 ADVERSE REACTIONS - During clinical trials with econazole nitrate topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the econazole nitrate and vehicle arms. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Trifluent Pharma at 1-800-927-5191 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 09/2025

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to econazole nitrate topical foam or vehicle (246 subjects were exposed to econazole nitrate topical foam, 1% and 249 were exposed to vehicle).

Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days. During clinical trials with econazole nitrate topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the econazole nitrate and vehicle arms.

🔄 Drug Interactions 77 words ▾

7 DRUG INTERACTIONS -

7.1Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

👥 Use in Specific Populations ~1 min read ▾

8 USE IN SPECIFIC POPULATIONS -

8.1Pregnancy - Pregnancy Category C There are no adequate and well-controlled trials with econazole nitrate topical foam in pregnant women. Econazole nitrate topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats.

Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

8.3Nursing Mothers It is not known whether econazole nitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when econazole nitrate is administered to a nursing woman. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups.

8.4Pediatric Use Of the 173 subjects treated with econazole nitrate topical foam, 1% in the clinical trials, 2 subjects were 12 to 17 years old. In a pediatric maximal use trial, econazole nitrate topical foam, 1% was applied once daily to eighteen subjects aged 12 to 17 years with interdigital tinea pedis for 28 days [ see Clinical Pharmacology (12.3) ]. The safety findings for subjects 12 to 17 years were similar to those in adult population.

8.5Geriatric Use Of the 173 subjects treated with econazole nitrate topical foam, 1% in the adult clinical trials, 6 subjects were 65 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

🤰 Pregnancy 108 words ▾

8.1Pregnancy - Pregnancy Category C There are no adequate and well-controlled trials with econazole nitrate topical foam in pregnant women. Econazole nitrate topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats.

Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

🧒 Pediatric Use 78 words ▾

8.4Pediatric Use Of the 173 subjects treated with econazole nitrate topical foam, 1% in the clinical trials, 2 subjects were 12 to 17 years old. In a pediatric maximal use trial, econazole nitrate topical foam, 1% was applied once daily to eighteen subjects aged 12 to 17 years with interdigital tinea pedis for 28 days [ see Clinical Pharmacology (12.3) ]. The safety findings for subjects 12 to 17 years were similar to those in adult population.

🧓 Geriatric Use 41 words ▾

8.5Geriatric Use Of the 173 subjects treated with econazole nitrate topical foam, 1% in the adult clinical trials, 6 subjects were 65 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

🧬 Clinical Pharmacology ~2 min read ▾

12 CLINICAL PHARMACOLOGY -

12.1Mechanism of Action Econazole nitrate topical foam is an azole antifungal [ see Clinical Pharmacology (12.4) ] .

12.2Pharmacodynamics The pharmacodynamics of econazole nitrate topical foam, 1% have not been established .

12.3Pharmacokinetics The systemic absorption of econazole nitrate topical foam, 1% following topical application was studied in one clinical trial in adults and one clinical study in pediatric subjects. In the adult trial, 19 subjects (male and female) with tinea pedis applied econazole nitrate topical foam, 1% once daily for 29 days. Subjects applied a mean daily amount of 2.4 g of econazole nitrate topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles.

Blood samples were obtained on Day 29 at pre-dose and 1, 2, 4, 6, 8, and 12 hours after application. Results (mean ± SD) showed the time to reach peak plasma concentrations (T max ) was 6.8 ± 5.1 h with maximum concentration (C max ) of 417 ± 218 pg/ml. The area under the concentration time curve for the first 12 hours post application on Day 29 (AUC (0-12) ) was 3440 ± 1920 pg-h/ml.

In the pediatric trial, 18 subjects (male and female ages 12 - 17) with interdigital tinea pedis and positive fungal cultures were treated with econazole nitrate topical foam, 1% once daily for 4 weeks. Subjects applied a mean daily amount of 3.2 g of econazole nitrate topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 28 at pre-dose and 7 h and 11 h post-dose.

The mean ± SD econazole plasma concentration was 397 ± 289, 534 ± 745 and 575 ± 638 pg/mL at pre-dose and 7 h and 11 h post-dose, respectively.

12.4Microbiology - Mechanism of Action Econazole nitrate, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the fungistatic activity of econazole.

Mammalian cell demethylation is less sensitive to econazole inhibition. Activity in vitro and in clinical infections Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections [ see Indications and Usage (1) ]. Trichophyton rubrum Epidermophyton floccosum Trichophyton mentagrophytes

🧬 Mechanism of Action 19 words ▾

12.1Mechanism of Action Econazole nitrate topical foam is an azole antifungal [ see Clinical Pharmacology (12.4) ] .

📦 How Supplied / Storage and Handling 98 words ▾

16 HOW SUPPLIED/ STORAGE AND HANDLING Econazole nitrate topical foam, 1% is white to off-white foam supplied in 70g (NDC 73352-100-70) aluminum pressurized canister. Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze.

Econazole nitrate topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure.

Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.

📦 Storage and Handling 74 words ▾

Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze. Econazole nitrate topical foam is flammable.

Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers.

Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.

📋 Description 114 words ▾

11 DESCRIPTION Econazole nitrate topical foam, 1% contains the azole antifungal agent, econazole nitrate in an oil-in-water emulsion base consisting of the following inactive ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as a propellant. Each gram of econazole nitrate topical foam, 1% contains 10 mg of econazole nitrate, USP, in a white to off-white foam. Econazola nitrate topical foam, 1% is alcohol (ethanol)-free and for topical use only.

Chemically, econazole nitrate is 1-[2-{(4-chloro-phenyl)methoxy}-2-(2,4-dichlorophenyl) ethyl]-1H-imidazole mononitrate. Econazole nitrate has the molecular formula C 18 H 15 Cl 3 N 2 O. HNO 3 and a molecular weight of 444.70.

Its molecular structure is as follows: Chemical Structure

💬 Information for Patients 86 words ▾

17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) The patient should be instructed as follows: Inform patients that econazole nitrate topical foam, 1% is for topical use only. Econazole nitrate topical foam, 1% is not intended for oral, intravaginal, or ophthalmic use. Econazole nitrate topical foam, 1% is flammable; avoid heat, flame, and smoking during and immediately following application.

If a reaction suggesting sensitivity or chemical irritation develops with the use of econazole nitrate topical foam, 1%, use of the medication should be discontinued.

🍼 Nursing Mothers 58 words ▾

8.3Nursing Mothers It is not known whether econazole nitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when econazole nitrate is administered to a nursing woman. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups.

🧬 Pharmacokinetics ~1 min read ▾

12.3Pharmacokinetics The systemic absorption of econazole nitrate topical foam, 1% following topical application was studied in one clinical trial in adults and one clinical study in pediatric subjects. In the adult trial, 19 subjects (male and female) with tinea pedis applied econazole nitrate topical foam, 1% once daily for 29 days. Subjects applied a mean daily amount of 2.4 g of econazole nitrate topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles.

Blood samples were obtained on Day 29 at pre-dose and 1, 2, 4, 6, 8, and 12 hours after application. Results (mean ± SD) showed the time to reach peak plasma concentrations (T max ) was 6.8 ± 5.1 h with maximum concentration (C max ) of 417 ± 218 pg/ml. The area under the concentration time curve for the first 12 hours post application on Day 29 (AUC (0-12) ) was 3440 ± 1920 pg-h/ml.

In the pediatric trial, 18 subjects (male and female ages 12 - 17) with interdigital tinea pedis and positive fungal cultures were treated with econazole nitrate topical foam, 1% once daily for 4 weeks. Subjects applied a mean daily amount of 3.2 g of econazole nitrate topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 28 at pre-dose and 7 h and 11 h post-dose.

The mean ± SD econazole plasma concentration was 397 ± 289, 534 ± 745 and 575 ± 638 pg/mL at pre-dose and 7 h and 11 h post-dose, respectively.

🧬 Pharmacodynamics 15 words ▾

12.2Pharmacodynamics The pharmacodynamics of econazole nitrate topical foam, 1% have not been established .

🔬 Clinical Studies ~1 min read ▾

14 CLINICAL STUDIES In two multi-center, randomized, double-blind, vehicle-controlled clinical trials a total of 505 subjects with interdigital tinea pedis were randomized 1:1 to econazole nitrate topical foam or vehicle; subjects applied the assigned medication once daily for 4 weeks. The severity of erythema, scaling, fissuring, maceration, vesiculation, and pruritus were graded using a 4-point scale (none, mild, moderate, severe). Subjects had KOH examination and fungal cultures taken to confirm eligibility.

A total of 339 subjects with positive fungal cultures were evaluated for efficacy. Efficacy was evaluated on Day 43, 2 weeks post-treatment with treatment success being defined as complete cure (negative KOH and fungal culture and no evidence of clinical disease). The study population ranged in age from 12 to 71 years with 5 subjects less than 18 years of age at baseline.

The subjects were 71% male and 51% Caucasian. Table 1 presents the efficacy results for each trial. Table 1: Efficacy Results at Two Weeks Post-treatment (Day 43) Complete Cure, Effective Treatment and Mycological Cure Trial 1 Trial 2 Econazole Nitrate topical foam 1% N = 82 n(%) Foam Vehicle N = 83 n(%) Econazole Nitrate topical foam, 1% N = 91 n(%) Foam Vehicle N = 83 n(%) Complete cure a 19 (23.2%) 2 (2.4%) 23 (25.3%) 4 (4.8%) Effective treatment b 40 (48.8%) 9 (10.8%) 44 (48.4%) 9 (10.8%) Mycological cure c 56 (68.3%) 13 (15.7%) 61 (67.0%) 15 (18.1%) a Mycological cure and an absence of clinical signs and symptoms (erythema, scaling, fissuring, maceration, vesiculation, or pruritus). b Mycological cure and no or mild erythema and/or scaling with all other signs and symptoms absent. c Negative KOH and fungal culture.

🧪 Nonclinical Toxicology 41 words ▾

13 NONCLINICAL TOXICOLOGY -

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies to determine the carcinogenic potential of econazole nitrate topical foam have not been performed. Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 37 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies to determine the carcinogenic potential of econazole nitrate topical foam have not been performed. Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation.

📄 Patient Package Insert ~3 min read ▾

Patient Information Econazole nitrate topical foam, 1% Important information: Econazole nitrate topical foam is for use on skin only. Do not use Ecoza topical foam in your eyes or vagina. What is econazole nitrate topical foam?

Econazole nitrate topical foam is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. What should I tell my doctor before using Econazole nitrate topical foam? Before using econazole nitrate topical foam, tell your doctor about all of your medical conditions, including if you: are pregnant or plan to become pregnant.

It is not known if econazole nitrate topical foam will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if econazole nitrate topical foam passes into your breast milk. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use econazole nitrate topical foam? See the detailed Instructions for Use for information about how to use econazole nitrate topical foam. Use econazole nitrate topical foam exactly as your doctor tells you to use it.

Apply econazole nitrate topical foam to the affected skin areas of your feet 1 time a day for 4 weeks. If econazole nitrate topical foam gets in or near your eyes, rinse them well with water. Wash your hands after you apply econazole nitrate topical foam.

What should I avoid while using econazole nitrate topical foam? Econazole nitrate topical foam is flammable. Avoid heat, flame and smoking while applying and right after you apply econazole nitrate topical foam to your skin.

What are the possible side effects of econazole nitrate topical foam? Econazole nitrate topical foam may cause skin reactions at the treatment site. Tell your doctor if you have any skin reactions on the areas of your skin treated with econazole nitrate topical foam.

These are not all the possible side effects of econazole nitrate topical foam. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store econazole nitrate topical foam? Store econazole nitrate topical foam at room temperature, between 68°F to 77°F (20°C to 25°C). Do not refrigerate or freeze econazole nitrate topical foam.

Do not store econazole nitrate topical foam in direct sunlight. Econazole nitrate topical foam is flammable. Keep the econazole nitrate topical foam canister away from heat and temperatures above 120°F (49°C), even if the canister is empty.

Do not puncture or burn the econazole nitrate topical foam canister. Keep econazole nitrate topical foam and all medicines out of the reach of children. General information about the safe and effective use of econazole nitrate topical foam Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your doctor or pharmacist for information about econazole nitrate topical foam that is written for health professionals. Do not use econazole nitrate topical foam for a condition for which it was not prescribed. Do not give econazole nitrate topical foam to other people, even if they have the same symptoms that you have.

It may harm them. What are the ingredients in econazole nitrate topical foam? Active ingredient: econazole nitrate USP Inactive Ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as a propellant.

Manufactured for Trifluent Pharma, LLC, San Antonio, TX 78213 P/N 141384 For more information call Trifluent Pharma, LLC at 888927-5191 This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 9.2025

📖 Instructions for Use ~2 min read ▾

Instructions for Use Econazole Nitrate Topical Foam, 1% Important information: econazole nitrate topical foam is for use on skin only. Do not use econazole nitrate topical foam in your eyes or vagina. Parts of econazole nitrate topical foam Canister.

(See Figure A ) Figure A How to apply econazole nitrate topical foam: Step 1: Before you apply econazole nitrate topical foam, shake the econazole nitrate topical foam canister for about 5 seconds. Step 2: Remove the cap and turn the econazole nitrate topical foam canister upside down over the palm of your hand. Step 3: Press down firmly on the actuator until there is a small amount of foam about the size of a golf ball in the palm of your hand.

(See Figures B and C ) Figure B Figure C Step 4: Use your finger-tips to scoop up small amounts of econazole nitrate topical foam and apply to the affected skin areas on your feet. Gently rub the foam into the skin. (See Figure D ) Figure D Step 5: You should apply econazole nitrate topical foam to your toes, to the spaces between your toes, and to the surrounding areas 1 time a day for 4 weeks or as prescribed by your doctor.

Step 6: Replace the cap. Wash your hands after applying econazole nitrate topical foam. How should I store econazole nitrate topical foam?

Store econazole nitrate topical foam at room temperature, between 68°F to 77°F (20°C to 25°C). Do not refrigerate or freeze econazole nitrate topical foam. Do not store econazole nitrate topical foam in direct sunlight.

Econazole nitrate topical foam is flammable. Keep the econazole nitrate topical foam canister away from heat and temperatures above 120°F (49°C), even if the canister is empty. Do not puncture or burn the econazole nitrate topical foam canister.

Keep econazole nitrate topical foam and all medicines out of the reach of children. This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured for Trifluent Pharma, LLC, San Antonio, TX 78213 Issued: 09/2025 Container Figure B Figure C Figure D

📄 Package Label / Principal Display Panel 38 words ▾

PRINCIPAL DISPLAY PANEL - 70 g Canister Label NDC 73352-100-70 Econazole nitrate topical foam, 1% For Topical Use Only Not for ophthalmic, oral or intravaginal use. Keep Out of Reach of Children Rx Only Net Wt 70g Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q4 2025 – Q1 2026 · 2 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
234
Units reimbursed last 4 qtrs
35.4K
Gross reimbursed last 4 qtrs
$840.2K
Avg / prescription
$3,590.42
Avg / unit
$23.7199
Latest quarter Q1 2026
39Rx
Fee-for-service vs managed care ⓘ
100% FFS
Fee-for-service · 234 Rx Managed care · 0 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: 30,940 units · 969 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: 4,480 units · 76.2 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
76.2969
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Nevada 969 /100k
2 Colorado 76.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Econazole Nitrate — the program that covers self-administered drugs. 3 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Econazole Nitrate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$1.65M
Claims incl. refills
37.4K
Beneficiaries
29.7K
Spend / beneficiary
$55.48
Spend / claim
$44.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Econazole Nitrate — the ingredient across all brands.

Top reported reactions

Fatigue60
Rash50
Dyspnoea47
Pain47
Nausea44
Diarrhoea42
Dizziness41

Age at onset

Adolescent1
Adult62
Elderly79

Reporter sex

921 reports
Male · 47%
Female · 53%
Unknown · 0%

Serious outcomes

Hospitalization332
Death53
Disabling26
Life-threatening23
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 73 33
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Trifluent Pharma, LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Trifluent Pharma, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.